Clinical trials: Dosimetry
Retinal Diseases
Evaluating the Safety of the SPECTRALIS CENTAURUS Device
The objective of this clinical trial is to evaluate the safety of the SPECTRALIS CENTAURUS device (HuCE-optoLab, BFH TI, Biel, CH) in a clinical setting on patients with retinal diseases.
- Trial name
- CENTAURUS (NCT04968756)
- Testing
- Selective retina therapy SPECTRALIS CENTAURUS device
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Prostate Cancer
US-CT Fusion for Post Implant Dosimetry
Post implant dosimetry is an essential part of quality assurance after permanent seed prostate brachytherapy. CT imaging is the standard of assessment but due to contouring uncertainties, MR-CT fusion is preferred.
- Trial name
- NCT03692104
- Testing
- transrectal ultrasound
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- British Columbia Cancer Agency
Solid Tumor, Adult, Bladder Cancer
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
This is an open-label pilot study of a new PET/CT imaging agent MNPR-101-DFO*-89Zr in patients with solid tumor cancers. These cancers may include bladder/urothelial, triple-negative breast, lung, colorectal, gastric, ovarian…
- Conditions
- Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer
- Trial name
- NCT06337084
- Testing
- MNPR-101-DFO*-89Zr, PET/CT Diagnostic Imaging
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- Monopar Therapeutics
Hypoxic Tumours
A Radiopharmacokinetic and Radiodosimetric Phase I Imaging Study of 18F-FAZA
Hypoxia (little of no oxygen) is considered to be an important characteristic of a patient's tumour that may help predict patient outcomes and/or help inform patient management decisions.
- Trial name
- NCT00756691
- Testing
- 18F-FAZA
- Sponsor
- AHS Cancer Control Alberta
Metastatic Castration-resistant Prostate Cancer
177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
This is a pilot study to assess the safety and measure image-based absorbed dose of 177Lu-PSMA-EB-01, a new PSMA-specific radiopharmaceutical, in patients with metastatic castration resistant prostate cancer (mCRPC) who will…
- Trial name
- NCT05613738
- Testing
- 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01, 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01, 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Peking Union Medical College Hospital
Parkinson Disease, Dementia With Lewy Bodies
[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
Study goal: The goal of this prospective head to head comparison is to evaluate the effectiveness of [18F]-MFBG PET in assessing cardiac innervation, comparing it with [123I]-MIBG SPECT The study's primary focus is on…
- Conditions
- Parkinson Disease, Dementia With Lewy Bodies, MSA - Multiple System Atrophy, Alzheimer Disease
- Trial name
- NCT06120049
- Testing
- [18F]-MFBG PET CT, [18F]-FE-PE2I PET CT or PET MRI, [123I]-MIBG SPECT CT
- Where
- 2 sites in Belgium
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- prof. dr. Koen Van Laere
Rectum Cancer, Recurrent, Brachytherapy, Radioisotope
The Physical Dosimetry Study and Preliminary Clinical Results of 3D-printing Non Co-planar Template Assisted With CT-guidance for Iodine-125 Seed Brachytherapy in Pelvic Recurrent Rectum Carcinoma After Surgery and External Beam Radiotherapy
This study observes the efficacy and side effects of 3D-printing non co-planar template(3D-PNCT) assisted with CT-guidance for radioactive Iodine-125 seed(RIS) brachytherapy in pelvic recurrent rectum carcinoma retrospectively…
- Trial name
- NCT03890926
- Testing
- radioactive Iodine-125 seed implantation under the guidance of 3D template
- Volunteers
- 66 people
- Sponsor
- Peking University Third Hospital
Head and Neck Neoplasms, Lung Neoplasms
Imaging Study for FdCyd and THU Cancer Treatment
Background: The drugs FdCyd (also called 5-fluoro-2'-deoxycytidine) and THU (also called tetrahydrouridine) are being used in a cancer treatment study. Not a lot is known about how FdCyd works in the body.
- Conditions
- Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
- Trial name
- NCT01479348
- Testing
- [F-18]-5-FLUORO-2'-DEOXYCYTIDINE, Tetrahydrouridine intravenous (IV), Tetrahydrouridine (oral)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
ARtificial Intelligence for Gross Tumour vOlume Segmentation
Identifying the outline of a Gross Tumour Volume (GTV) in lung cancer is an essential step in radiation treatment. Clinical research, such as radiomics and image-based prognostication, requires the GTV to be pre-defined on…
- Trial name
- ARGOS (NCT05775068)
- Testing
- Radiotherapy
- Where
- Netherlands
- Volunteers
- 2,000 people
- Sponsor
- Maastricht Radiation Oncology
Metastatic Prostate Cancer
A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
A randomised, multi-centre, intra-patient imaging and dosimetry crossover study of lutetium (177Lu) rhPSMA 10.1 and lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with non-curative metastatic prostate cancer
- Trial name
- NCT06516510
- Testing
- lutetium (177Lu) rhPSMA 10.1 and Pluvicto®
- Where
- 6 sites in United States, Netherlands and 1 more
- Volunteers
- 17 people
- Sponsor
- Blue Earth Therapeutics Ltd
Lung Cancer
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients
This is an open-label dynamic whole-body PET/CT (positron emission tomography/computed tomography) study for investigation of radiation dosimetry, plasma pharmacokinetics, biodistribution, safety and diagnostic performance of…
- Trial name
- GRGDLC (NCT01527058)
- Testing
- 68Ga-BNOTA-PRGD2
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Malignant Mesothelioma, Non-Small Cell Lung Carcinoma
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
This phase I trial studies the side effects and how well light dosimetry system works during photodynamic therapy with porfimer sodium in treating participants with malignant mesothelioma , non-small cell lung cancer or any other…
- Conditions
- Malignant Mesothelioma, Non-Small Cell Lung Carcinoma, Pleural Disorder
- Trial name
- NCT03678350
- Testing
- Light Dosimetry for Intranoperative Therapy, Photodynamic Therapy, Porfimer Sodium
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Hyperthyroidism
Optimization With a Gamma Camera of the Individualized Patient Dosimetry in Radioiodine Therapy of Thyroid Diseases
This is a pilot, single-center, prospective, open-label clinical investigation of a medical device (ambulatory gamma camera " MoTI " (Mobile Therapy Imager)) for patients with hyperthyroidism (Graves' disease, toxic nodule and…
- Trial name
- THIDOS (NCT06371339)
- Testing
- Additional acquisitions with the investigational gamma-camera " MoTI ".
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Institut Claudius Regaud
B-cell Lymphoma
High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma
90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
- Trial name
- HITT (NCT00761384)
- Testing
- 90Y-ibritumomab
- Where
- Sweden
- Volunteers
- 7 people
- Sponsor
- Lund University Hospital
Prostate Cancer, Prostatic Neoplasm
68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical
This is a preliminary evaluation of a radiotracer's biodistribution in human subjects. It is a prospective, single-centre, open-label, single group assignment interventional study.
- Conditions
- Prostate Cancer, Prostatic Neoplasm, Prostatic Disease, Urogenital Neoplasms
- Trial name
- NCT04831307
- Testing
- [68Ga]Ga-HTK03149 PET/CT
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Breast Cancer, Colorectal Cancer
A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors
The primary objectives of this trial are to evaluate the safety and dosimetry of [68Ga]Ga-OncoFAP for detection/imaging of solid tumors.
- Conditions
- Breast Cancer, Colorectal Cancer, Oesophageal Cancer, Pancreas Adenocarcinoma
- Trial name
- FAPrimo (NCT05784597)
- Testing
- [68Ga]Ga-OncoFAP administration
- Where
- 5 sites in Italy
- Volunteers
- 18 people
- Sponsor
- Philogen S.p.A.
Nevi and Melanomas
Assessing Gene-Environment Interactions in Clinical Presentation of Nevi and Melanoma
This research study is designed to better understand the role of genetics, sun-exposure and phenotypic factors in melanoma.
- Trial name
- NCT03783325
- Testing
- UV Counseling, UV Photo, Biological Sample
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Breast Carcinoma
Impact of Tumor Bed Localisation on Dosimetry Boost Irradiation in Patients Undergoing Breast Conserving Surgery
PRIMARY STUDY OBJECTIVES: To evaluate dosimetric outcomes in tumor bed boost irradiation in patients undergoing breast conservative surgery using three different surgical techniques SECONDARY OBJECTIVES- Evaluation of cosmesis in…
- Trial name
- NCT03710018
- Where
- India
- Volunteers
- 21 people
- Sponsor
- Tata Memorial Centre
Solid Tumor, Unspecified, Adult
The Safety and Dosimetry Study of 177Lu-LNC1004 Injection
This proposal is a phase I, open-label study of a 4-Dose Regimen of Escalating Doses of 177Lu-LNC1004 Injection in patients with recurrent or metastatic, fibroblast activation protein-positive solid tumors.
- Trial name
- NCT05723640
- Testing
- 177Lu-LNC1004 Injection group 1 radionuclide therapy, 177Lu-LNC1004 Injection group 2 radionuclide therapy, 177Lu-LNC1004 Injection group 3 radionuclide therapy
- Where
- Singapore
- Volunteers
- 11 people
- Sponsor
- Yantai LNC Biotechnology Singapore PTE. LTD.
Cervical Cancer
Hydrogel Spacer During Definitive Radiotherapy for Cervical Cancer
This prospective, single-center study will evaluate the feasibility, spatial stability, and dosimetric effects of an absorbable hydrogel spacer placed between the cervix/vagina and rectum before definitive radiotherapy for…
- Trial name
- Hydrogel-RT (NCT07904182)
- Testing
- Absorbable Hydrogel Spacer
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital